Sekisui announces Acucy flu test clearance

2019 10 09 20 17 0927 Influenza Virus 400

Sekisui Diagnostics announced that its Acucy influenza A and B test has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration (FDA).

The test is designed for use with the company's Acucy point-of-care reader, which Sekisui said can be used to test nasal and nasopharyngeal swabs onsite as well as in laboratory settings. Sekisui announced the clearance on October 8, following an FDA decision on December 17, 2018.

Sekisui also markets the Osom Ultra (manual read lateral flow) and Silaris molecular point-of-care tests for influenza A and B.

Page 1 of 7
Next Page